The domestic bio medicine market is about to break out! Pharmaceutical enterprises open layout mode

[China Pharmaceutical network industry trends] Biopharmaceutics is one of the sub industries with rapid development in the pharmaceutical industry in recent years It can be seen that global Biopharmaceutics are developing rapidly and the market scale is huge, and China's Biopharmaceutics are also keeping pace From 2012 to 2016, the market scale of biological drugs in China has increased from 62.7 billion yuan to 152.7 billion yuan, with a compound annual growth rate of 24.9% In January 2017, the 13th five year plan for the development of biological industry (hereinafter referred to as "the plan") pointed out that biomedicine ushered in a new round of development opportunities The plan emphasizes that during the 13th Five Year Plan period, China's biomedical industry will focus on the development of major disease chemicals, biotechnology drugs, new vaccines, new cell therapy preparations and other innovative drug categories According to the plan, by 2020, China's biomedical industry will achieve an industrial sales revenue of 4.5 trillion yuan, accounting for 3.6% of the national industrial added value With the support of policy, the follow-up of national medical insurance, the investment of research and development resources and funds, and the continuous progress of technology, and with the successive expiration of heavyweight biopharmaceuticals, China's biopharmaceuticals market as innovative generic drugs is about to break out The industry expects that China's biopharmaceuticals will maintain a compound annual growth rate of 16.4% from 2016 to 2021, and reach a market scale of 326.9 billion yuan by 2021 There will be promising investment opportunities in the pharmaceutical industry in China In this good background, many well-known pharmaceutical enterprises in China have begun to layout and take actions For example, Hengrui pharmaceutical, Fosun Pharmaceutical, Kanghong pharmaceutical, Anke biology, Watson biology, Lizhu group, etc Hengrui medicine: Hengrui medicine announced in March that the company's biological similar drug product bevacizumab was approved for clinical trials According to IMS database, the sales volume of bevacizumab injection in China in 2017 was about US $100 million At present, dozens of domestic enterprises have obtained the clinical trial approval of Bevacizumab Injection and its similar products, and there is no such product and its similar products approved for production The industry believes that Hengrui medicine has a positive layout and bevacizumab is expected to play an important role in the company's future cancer treatment combined drug system Fosun Pharmaceutical: in January 2018, CDE released the announcement of drug registration application to be included in the priority review procedure (the 26th batch), and the listing application of "rituximab injection", a subsidiary of Fosun Pharmaceutical, was included in the priority review announcement list It is expected that rituximab will be approved within this year This is a macromolecular monoclonal antibody of Fosun medicine, and it is also a biological similar medicine in China Kanghong pharmaceutical: products enter overseas According to the annual report of Kanghong pharmaceutical, the company's operating revenue in recent years is bullish year by year In 2017, the operating profit reached 788 million yuan, an increase of 41.45% year on year Its main product, conbercept ophthalmic injection, is about to enter the performance exchange period After entering the continuous volume of medical insurance in 2017, it is expected to enter the overseas market and seize nearly 10 billion US dollars Kanghong pharmaceutical industry will usher in a new turning point in performance in 2018 Anke biology: it is expected to develop biological drugs On January 24, 2018, Anke biology announced that it signed a technology transfer agreement with Jiangsu aosaikang, and obtained the clinical research approval and related technology of "recombinant anti VEGF humanized monoclonal antibody injection" The industry believes that the acquisition of VEGF products under research means that it is further extended and enriched in the direction of bio innovative drugs In the future, the company is expected to develop into a high-tech company characterized by bio drugs and bio therapy Watson Bio: the class 1 new drug independently researched and developed has been approved for clinical application Recently, Watson bio released the "notice on the approval of clinical trials of gb235 McAb for injection developed by Jiahe bio, a subsidiary of Watson bio The independently innovated and developed gb235 McAb for injection developed by Jiahe bio Pharmaceutical Co., Ltd., a holding subsidiary of Watson bio, has been approved for clinical study According to the announcement, the new drug is a class 1 innovative therapeutic biological product applied for clinical research by Jiahe biology in China It is independently innovated and developed by Jiahe biology and has core independent intellectual property rights Lizhu group: the heavyweight variety is expected to be approved in the near future By the end of 2017, Lizhu's "patozumab" will obtain independent intellectual property rights, and enter phase I clinical, as well as the registration application status of eprazole raw material application and production will be changed to "approved pending certification", which means that the heavyweight variety is expected to be approved in the near future.